In This Issue .................................................................................................................. A11
Clinical Connections ...................................................................................................... A13
Special Articles
Editorial: Herpes Zoster: Fear the Infection, Value the Solution ................................. 1917
John J. Cush
Editorial: Lupus, the Chameleon: Many Disguises Difficult to Capture ......................... 1921
Susan Manzi and Joan Merrill
Review: Enhancers in Autoimmune Arthritis: Implications and Therapeutic Potential ... 1925
Janneke G. C. Peeters, Sebastiaan J. Vastert, Femke van Wijk, and Jorg van Loosdrecht
Rheumatoid Arthritis
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis .......................... 1937
Michael E. Weinblatt, Clifton O. Bingham III, Gerd-Rüdiger Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Brenda VanLunen, Cécile Ecoffet, Christopher Cioffi, and Paul Emery
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials ................................. 1949
Frédéric Vanhoutte, Minodoru Mazur, Oleksandr Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namous, René Galien, Luc Meuleners, and Gerben van ’t Klooster
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy 1960
Kevin L. Winthrop, Jeffrey R. Curtis, Stephen Lindsey, Yoshiya Tanaka, Kunihiro Yamaoka, Hernan Valdez, Tomohiro Hirose, Chudy I. Nduaka, Lizy Wang, Alan M. Mendelsohn, Haiyun Fan, Connie Chen, and Eustratios Bananis
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial .................................................. 1969
Osteoarthritis
Brief Report: Induction of Matrix Metalloproteinase Expression by Synovial Wnt Signaling and Association With Disease Progression in Early Symptomatic Osteoarthritis ................................................................. 1978
Martijn H. van den Bosch, Arjen B. Blom, Fons A. van de Loo, Marije I. Koenders, Floris P. Lafeber, Win B. van den Berg, Peter M. van der Kraan, and Peter L. van Lent
Spondyloarthritis
Intestinal Metabolites Are Profoundly Altered in the Context of HLA–B27 Expression and Functionally Modulate Disease in a Rat Model of Spondyloarthritis ........................................... 1984
Mark Asquith, Sean Davin, Patrick Stauffer, Claire Michell, Cathleen Janowitz, Phoebe Lin, Joe Ensign-Lewis, Jason M. Kinchen, Dennis R. Koop, and James T. Rosenbaum
Systemic Lupus Erythematosus
Maria Dall’Era, Miriam G. Cisternas, Kurt Snipes, Lisa J. Herrinton, Caroline Gordon, and Charles G. Helmick
The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program ............................................. 2006
Peter M. Izmirly, Isabella Wan, Sara Sahli, Jill P. Buyon, H. Michael Belmont, Jane E. Salmon, Anca Askanase, Joan M. Bathon, Laura Geraldino-Pardilla, Yousaf Ali, Ellen M. Ginzler, Chaim Putterman, Caroline Gordon, Charles G. Helmick, and Hilary Parton
**Clinical Images**
Livedoid Vasculopathy
_Evangelia Zampeli and Haralampos M. Moutsopoulos_ ........................................ 2096

**ACR Announcements** ................................................................. A16

**Cover image:** The figure on the cover (from Peeters et al, page 1927) illustrates superenhancer-driven gene expression. Superenhancers are extremely large enhancers, characterized by increased histone acetylation (green ovals) and augmented protein binding, leading to increased gene expression. Superenhancers preferentially regulate genes associated with cell identity and disease, such as autoimmune arthritis, and are enriched for disease-associated single-nucleotide polymorphisms.